Drug intelligence / Profile preview

GT30(x)

Development stage: Unknown
Lead developer: Grid Therapeutics
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

GT30(x) is an antibody drug candidate that has reached early Phase 1 clinical trials for the treatment of solid tumors. Specific details regarding its mechanism of action, molecular target, or further pharmacological properties are not available in the public domain. The drug appears to be under investigation in the United States as of January 2022[1].

Other names: GT-30 (x)

Beyond the preview

Go deeper on GT30(x).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT30(x).

Explore the full profile